Sarepta Therapeutics

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Sarepta reports robust earnings, poised for gene therapy milestone

Sarepta Therapeutics delivered strong financial performance in Q4 2022, driven by revenue growth and positive market reception of its RNA-based PMO therapies.
While facing challenges in managing expenses and navigating regulatory uncertainties, the company is strategically positioned to capitalize on growth opportunities in gene therapy and market expansion.
By focusing on innovation, operational readiness, and market access, Sarepta aims to secure a leading position in Duchenne muscular dystrophy treatment and drive sustainable revenue growth.

Sarepta Therapeutics exceeds Q1 revenue expectations, poised for growth

Sarepta Therapeutics delivered strong financial results in Q1 2023, exceeding expectations and showcasing market confidence in their growth trajectory.
The company's proactive approach to patient access, payer engagement, and therapy development highlights their commitment to addressing unmet medical needs and advancing innovative treatments.
While facing pricing challenges and regulatory decisions, Sarepta's focus on research, partnerships, and therapy expansion presents opportunities for sustained growth and impact.
With a robust pipeline, positive payer discussions, and ongoing studies, Sarepta is poised to make a significant difference in treating rare diseases and improving patient outcomes.

Sarepta Therapeutics excels in Q2 with ELEVIDYS approval and patient-focused strategies

Sarepta Therapeutics demonstrated strong performance in Q2 2023 with positive revenue growth and progress in clinical studies and commercial activities.
Despite challenges in administrative processes and label expansion, the company's focus on patient care and operational efficiency remains a key strength.
Opportunities lie in broadening therapy access, addressing limitations, and streamlining patient access post label expansion for enhanced market reach and treatment efficiency.

Sarepta Therapeutics excels in Q3 earnings, eyes label expansion

Sarepta Therapeutics delivered robust financial performance in Q3 2023, driven by the success of ELEVIDYS and PMOs. Despite challenges in regulatory processes and market competition, the company's strategic focus on label expansion and patient access presents significant growth opportunities.

Sarepta Therapeutics reports robust Q4 earnings and targets pipeline expansion

Sarepta Therapeutics delivered strong financial results in Q4 2023, showcasing revenue growth and profitability. Despite facing challenges such as potential margin declines and clarity issues, the company is well-positioned to capitalize on opportunities for pipeline advancement and expansion.

Sarepta Therapeutics excels in Q1 earnings, eyes label expansions

Sarepta Therapeutics delivered strong financial performance in Q1 2024, driven by robust revenue growth and steady demand for key products like ELEVIDYS.
The company's strategic focus on label expansions and innovative R&D efforts positions it well for future success in addressing unmet medical needs and driving market expansion.
While facing challenges in patient demographics and operational readiness, Sarepta remains well-capitalized and poised to capitalize on upcoming opportunities for growth and market leadership.

Sarepta Therapeutics reports robust Q2 revenue and eyes therapy expansion

Sarepta Therapeutics is experiencing strong revenue growth driven by ELEVIDYS, with a focus on patient outcomes and manufacturing capacity. Challenges include addressing bottlenecks and patient prioritization, while opportunities exist in therapy development and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

In a gene therapy study for patients with Duchenne muscular dystrophy, the primary endpoint was not met.

Sarepta Stock Sinks on Mixed Gene Therapy Results

Sarepta unveiled mixed results late Monday for a gene therapy that targets a muscle-wasting disease in boys. SRPT stock was halted.

Sarepta Therapeutics Stock Halted After Unveiling Mixed Results For Its First Gene Therapy

Sarepta Therapeutics' gene therapy to treat Duchenne muscular dystrophy failed to reach statistical significance in a late-stage trial, the company reported after the bell on Monday.

Sarepta's gene therapy fails to meet primary goal in rare muscular dystrophy trial

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics announces the topline results from EMBARK, a global pivotal study of ELEVIDYS gene therapy for Duchenne muscular dystrophy.

Sarepta Therapeutics Announces Topline Results from EMBARK, a Global Pivotal Study of ELEVIDYS Gene Therapy for Duchenne Muscular Dystrophy

Capricor Therapeutics

Recent dip in CAPR's stock price following update on regulatory pathway for CAP-1002 and cash raise represents a buying opportunity. Completion of enrollment of Cohort A of ongoing Phase 3 trial of CAP-1002 is expected in Q4 2023, topline results in Q4 2024 and BLA submission in 2025. Risks for CAPR include; failure of ongoing Phase 3 trial, regulatory delays and need for more dilutive cash raise by the end of 2024.

Capricor Therapeutics, Sarepta Therapeutics: A Promising Clinical-Stage Biotech And A Commercial-Stage Leader In Duchenne Muscular Dystrophy

Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sarepta Therapeutics (SRPT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2023 financial results after the Nasdaq Global Market closes on Wednesday, Nov. 1, 2023. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its third quarter 2023 financial results. The event will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sar.

Sarepta Therapeutics to Announce Third Quarter 2023 Financial Results

The consensus price target hints at a 50.6% upside potential for Sarepta Therapeutics (SRPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Believe Sarepta Therapeutics (SRPT) Could Rally 50.6%: Here's is How to Trade

Biogen

bluebird bio

BioMarin Pharmaceutical

CRISPR Therapeutics

Editas Medicine

Intellia Therapeutics

Novartis

Regeneron Pharmaceuticals

Solid Biosciences

It's not often that you see a company whose main product comes with a price tag of over $2 million, but that's the case with biotechs BioMarin Pharmaceutical NASDAQ: BMRN and Sarepta Therapeutics NASDAQ: SRPT, which are developing gene therapies. ‘

Are Gene Therapy Stocks The Market's Next Big Winners?

Shopify

Sarepta Therapeutics is successfully developing treatments for a rare and devastating disease. Shopify's recent moves should make it even stronger in the fast-growing e-commerce industry.

2 Top Growth Stocks to Buy With $500

Sarepta Therapeutics, Inc. results from pivotal EMBARK study, using ELEVIDYS for the treatment of ambulatory DMD patients between ages 4 to 7 expected in Q4 of 2023. The primary endpoint being met in EMBARK study would allow label expansion for all ambulatory DMD patients, regardless of age. Another expansion opportunity for ELEVIDYS would be the targeting of non-ambulatory DMD patients; This might be possible with a successful outcome from the ENVISION study.

Sarepta: Broad Label Expansion Possible With Q4 2023 Catalyst

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced 25 recipients of Route 79, The Duchenne Scholarship Program for the 2023-2024 academic year. Of the 25 recipients, academic scholarships will be awarded to 20 individuals living with Duchenne muscular dystrophy and to five siblings of individuals living with Duchenne. Each recipient will receive a scholarship of up to $5,000. “On behalf of Sare.

Sarepta Therapeutics Announces Recipients of the 6th Annual Route 79, The Duchenne Scholarship Program, for the 2023-2024 Academic Year

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference on Monday, Sept. 11, 2023 at 8:40 a.m. E.T. The fireside chat will be held at the Sheraton New York in New York, NY. The presentation will be webcast live under the Events & Presentations section of the investor relation.

Sarepta Therapeutics to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock?

Sarepta Therapeutics (SRPT) Up 12.7% Since Last Earnings Report: Can It Continue?

Quest Diagnostics

Quest and Sarepta Therapeutics Expand Collaboration to Develop AAV Companion Diagnostics (CDx) for Sarepta's Gene Therapies SECAUCUS, N.J. and CAMBRIDGE, Mass.

Quest Diagnostics Granted FDA Breakthrough Designation for its Adeno-associated virus (AAV) Test

Wall Street is expecting big things from the rare disease specialist Sarepta Therapeutics in 2023 and beyond. However, the company does face some important challenges that could stunt its growth.

Is Sarepta Therapeutics Stock a Top Growth Vehicle?

Sarepta's (SRPT) second-quarter 2023 earnings beat estimates. Though total revenues register strong year-over-year growth during the quarter, the same misses the mark.

Sarepta (SRPT) Q2 Loss Narrower Than Expected, Sales Miss

Sarepta Therapeutics, Inc. (NASDAQ:SRPT ) Q2 2023 Earnings Conference Call August 2, 2023 4:30 PM ET Company Participants Francesca Nolan - IR Director Doug Ingram - President and CEO Louise Rodino-Klapac - EEVP, Chief Scientific Officer and Head of Research & Development Dallan Murray - EVP & Chief Customer Officer Ian Estepan - EVP & CFO Conference Call Participants Colin Bristow - UBS Brian Abrahams - RBC Capital Markets Tazeen Ahmad - Bank of America Gena Wang - Barclays Salveen Richter - Goldman Sachs Gil Blum - Needham & Company Uy Ear - Mizuho Securities Michael Ulz - Morgan Stanley Danielle Bongero - Raymond James Ritu Baral - TD Cowen Anupam Rama - JPMorgan Kristen Kluska - Cantor Fitzgerald John Boyle - William Blair Debjit Chattopadhyay - Guggenheim Securities Operator Good afternoon and welcome to the Sarepta Therapeutics Second Quarter 2023 Earnings Call. At this time, all participants are in listen-only mode.

Sarepta Therapeutics, Inc. (SRPT) Q2 2023 Earnings Call Transcript

Sarepta Therapeutics (SRPT) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $1.89. This compares to loss of $2.65 per share a year ago.

Sarepta Therapeutics (SRPT) Reports Q2 Loss, Misses Revenue Estimates

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the second quarter 2023. “With a positive Advisory Committee vote followed by the approval of ELEVIDYS in June, this quarter marks an historic milestone in the treatment of Duchenne muscular dystrophy. The launch of ELEVIDYS is off to a great start, with our first reimbursed infusion today, ahead of plan. In addition to mak.

Sarepta Therapeutics Announces Second Quarter 2023 Financial Results and Recent Corporate Developments

Exelixis

Sarepta is a leader in developing medicines for Duchenne muscular dystrophy. Exelixis has a proven track record in developing innovative cancer therapies.

2 Biotech Growth Stocks I'd Buy Right Now

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report second quarter 2023 financial results after the Nasdaq Global Market closes on Wednesday, August 2, 2023. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its second quarter 2023 financial results. The event will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.

Sarepta Therapeutics to Announce Second Quarter 2023 Financial Results

Sarepta Therapeutics (SRPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sarepta Therapeutics (SRPT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Sarepta reported a $516.8M loss in Q1 2023 but saw increased revenues ($253.5M) and holds $1.9B in assets. FDA's narrower approval for Elevidys impacted the stock but could expand with a successful confirmatory trial. Despite challenges, SRPT continues to progress, suggesting a viable long-term investment with a 'Hold' recommendation.

Sarepta Therapeutics: 'Hold' Amid Market Myopia

AbbVie

BioXcel Therapeutics

There are several reasons that investors should be cautious about buying or holding biotech stocks at this point. First, the Street is generally bearish on the sector lately.

News for Sarepta Therapeutics Stock (SRPT)